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ABSTRACT 
The purpose of this experiment was to determine whether the development of 
behavioral sensitization to 7-OH-DPAT could be prevented by concurrent treatments 
with the selective dopamine DI-type antagonist, SCH 23390. 
Thirty-two male Wistar albino rats served as subjects. Therefore, eight 
animals were randomly assigned to each of the four treatment groups: vehicle-
vehicle, vehicle-7-OH-DPAT (1.0 mg/kg), SCH 23390 (0.1 mg/kg)-vehicle, and SCH 
23390-7-OH-DPAT. During the seven pretreatment sessions, each animal was first 
injected with either SCH 23390 or vehicle, and then 15 min later injected with either 
7-OH-DPAT or vehicle. Fifteen min following the second injection, each animal was 
tested for locomotor activity for 120 min. On session eight, all animals were first 
given an injection of vehicle, followed by a 1.0 mg/kg injection of7-OH-DPAT 15 
min later. Fifteen min following the second injection animals were tested for 120 min. 
All injections were subcutaneous (sc) and all sessions were separated by a 48 hr drug 
free interval. 
The major findings were as follows: a) repeated treatments with 7-OH-DPAT 
(1.0 mg/kg) produced a progressive increase in distance traveled across both sessions 
and 20 min blocks within sessions, b) SCH 23390 treatments significantly suppressed 
locomotor activity, c) SCH 23390 given concurrently with 7-OH-DPAT effectively 
blocked the acute locomotor activating effects of7-OH-DPAT over sessions, d) 
pretreatment with 7-OH-DPAT significantly increased subsequent behavioral 
sensitivity to the activating effects of the 7-OH-DPAT challenge injection, e) prior 
treatments with SCH 23390 alone did not increase subsequent sensitivity to 7-OH-
DPAT and concurrent treatments of SCH 23390 and 7-OH-DPAT partially attenuated 
the development ofbehavioral sensitization to 7-OH-DPAT. 
The results of this experiment show that behavioral sensitization to 7-OH-
DPAT is similar to that of other dopamine D2-type agonists, such as quinpirole and 
bromocriptine (Mattingly et al., 1996; Wise & Carlezon, 1994). But, concurrent 
treatments with SCH 23390 and 7-OH-DPAT only partially blocked the development 
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of behavioral sensitization to 7-0H -DPAT measured after the challenge injection of 
7-0H-DPAT. Therefore, these findings suggest that the development of behavioral 
sensitization to 7-0H-DPAT and other dopamine DZ-type agonists is not the same. 
Although the basis for the differences is currently unknown, the differences suggest 
that the development of behavioral sensitization to dopamine DZ-type agonists is not 
mediated by a common neurochemical mechanism. 
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CHAPTER 1 
INTRODUCTION 
I. Psychostimulants and Behavioral Sensitization: 
Humans have used psychostimulant compounds derived from plants for 
centuries to increase mental alertness, to combat fatigue and depression, and to 
increase physical stamina (see Snyder, 1996). In the 1800's, the active ingredients of 
many of these preparations (e.g., cocaine from coca plant) were isolated, purified, and 
ultimately synthesized. This led to an increasing use and abuse of these agents. 
Indeed, amphetamine and cocaine continue to be among the most widely abused 
compounds available (see Snyder, 1996, for review). 
In humans, the acute administration of psychostimulant compounds such as 
cocaine produce a wide variety of generally positive effects ranging from a perceived 
increase in physical and mental arousal to feelings of euphoria. As might be expected, 
the positive effects tend to result in the repeated use of the stimulant. Unfortunately, 
the behavioral effects of psychostimulant drugs tend to change with repeated 
exposure. Initially, repeated psychostimulant use leads to withdrawal effects such as 
craving. In turn, craving is often followed by addiction, and in some cases compulsive 
drug seeking behaviors (Robinson & Berridge, 1993; Robinson & Becker, 1986; 
Berridge & Robinson, 1995). Moreover, the chronic use ofpsychostimulant drugs in 
high doses over a longer time frame may also lead to a number of psychiatric 
disorders ranging from anxiety and panic to paranoid psychosis (Robinson & 
Berridge, 1993; Robinson & Becker, 1986; Kalivas & Stewart, 1991). Although 
stimulant-induced craving and paranoia may dissipate with prolonged abstinence, 
evidence indicates that individuals previously addicted to psychostimulants remain 
supersensitive to these agents for years after withdrawal (Kalivas & Stewart, 1991; 
Ellinwood, 1967; Kramer, Fischman, & Littlefield, 1967). This latter finding may 
explain why stimulant addictions are highly resistant to treatment and relapse is 
common (Robinson & Berridge, 1993). 
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The behavioral effects ofpsychostimulant drug administration in animals are 
similar to those observed in humans. Cocaine and amphetamine, for example, greatly 
increase arousal and locomotor activity in rodents (Stewart & Vezina, 1989; 
Robinson & Becker, 1986; Post, Weiss, Pert, & Uhde, 1987), and these compounds 
are readily self-administered by both rodents and primates (Henry, Greene, & White, 
1989; Glowa, Rice, Matecka, & Rothman, 1997). Although it is difficult to evaluate 
craving and paranoia in animals, the behavioral effects of psychostimulant drugs do 
change with repeated administration. The most frequently observed effect of repeated 
stimulant administration in animals has been the phenomenon of behavioral 
sensitization (Kalivas & Stewart, 1991; Robinson & Becker, 1986). Behavioral 
sensitization refers to a progressive augmentation of the behavioral effects of a drug 
with repeated exposure. For example, numerous studies have indicated that the 
locomotor-activating effects of cocaine, as w~ll as most other stimulant-type drugs, 
progressively increase with repeated intermittent treatments (Mattingly, Gotsick, 
Salamanca, 1988; Segal & Schuckit, 1983). More recently, behavioral sensitization 
has also been reported for the rewarding effects of these compounds as well (Lett, 
1989). Thus, rather than producing tolerance with repeated exposure, the activating 
and rewarding effects of psycho stimulant drugs appear to increase with repeated 
exposure. Moreover, these changes in sensitivity appear to be relatively permanent, 
in that animals, like humans, remain supersensitive to these stimulants for months 
after drug-withdrawal (Mattingly et al., 1988). The many similarities between 
stimulant-induced addiction and psychosis in humans, and the development and 
persistence of behavioral sensitization in animals, have led many researchers to 
conclude that these two phenomenon are mediated by drug-induced alterations in the 
same neurochemical systems. Indeed, behavioral sensitization has become one of the 
major animal models for the study of stimulant abuse and stimulant-induced 
psychosis (Kalivas .& Stewart, 1991; Robinson & Becker, 1986; Robinson & 
Berridge, 1993). 
II. Role ofDopaminergic Neurotransmitter System and Behavioral Sensitization: 
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Although multiple neurotransmitter systems are undoubtedly involved, a great 
deal of research attention has focused upon the role of the neurotransmitter dopamine 
as a primary mediator of both drug abuse and behavioral sensitization (Kalivas & 
Stewart, 1991; Robinson & Becker, 1986). Nearly all psychostimulant drugs, as well 
as most other drugs of abuse, either directly or indirectly result in an increase in 
dopaminergic activity (Wise & Bozarth, 1985). Moreover, all drugs that produce 
behavioral sensitization result in an increased. stimulation of dopamine receptors 
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(Mattingly, Rowlett, Graff, & Hatton, 1991; Vezina & Stewart, 1989). Consequently, 
it is generally accepted that dopamine receptor stimulation is a critical factor in the 
development of behavioral sensitization. 
Recent research in molecular biology has identified five distinct dopamine 
receptors, which have been classified into two subfamilies based upon both physical 
and functional similarities. The dopamine receptor subtype within the DI subfamily 
(DI and D5 receptors) stimulate adenylate cyclase activity and are only found post-
synaptically. Receptor subtypes within the D2 subfamily (02, D3, D4 receptors) are 
either unlinked to, or inhibit, adenylate cyclase activity and are found both pre- and 
post-synaptically subfamilies (Lui, Cox, Greif, Freedman, & Waszczak, 1994; 
Schwartz, Giros, Martres, & Sokoloff, 1992). 
Over the past ten years, a number of drugs have been developed with 
relatively high selectivity for dopamine receptors within a specific subfamily, but few 
drugs have been identified that are selective for specific dopamine receptor subtypes 
within a subfamily. Consequently, although a great deal of research exists concerning 
the involvement ofD I-type and D2-type dopamine receptor subfamilies in the 
development of behavioral sensitization, the involvement of individual receptors 
within each subfamily is less clear. 
III. Selective Dopamine Agonists and Antagpnists and Behavioral Sensitization 
Recent research suggests the dopamine DI receptor subfamily is critical in the 
development of behavioral sensitization to psychostimulants. For example, chronic 
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administration of the direct DI/DZ-type dopamine agonist apomorphine results in the 
development of behavioral sensitization (Mattingly, et al., 1991; Rowlett, Mattingly, 
& Bardo, 199 I). However, concurrent treatments with the selective DI antagonist, 
SCH 23390, completely blocks the acute locomotor-activating effects of apomorphine 
and prevents the development of behavioral sensitization to apomorphine (Mattingly 
& Rowlett, 1989; Mattingly et al., 1991). In contrast, even though concurrent 
treatments with the DZ-type antagonist sulpiride block the acute locomotor-activating 
effects of apomorphine, concurrent treatment with sulpiride does not block the 
development of behavioral sensitization to apomorphine (Mattingly et al., 1991). 
These findings support the notion that the DI receptor subfamily is critical in the 
development of behavioral sensitization to apomorphine. Similar to the apomorphine 
findings, chronic administration of the indirect dopamine agonist amphetamine 
produces behavioral sensitization (Robinson & Becker, 1986; Stewart & Vezina, 
1989). Moreover, concurrent treatments with the DI antagonist, SCH 23390, blocks 
the acute effects of amphetamine and prevents the development of behavioral 
sensitization to amphetamine (Stewart & Vezina, 1989). Similar to apomorphine, co-
administration of a variety of dopamine D2 antagonists such as sulpiride, pimozide, 
metaclopromide, and RO-22-2586 do not block the development of behavioral 
sensitization to amphetamine (Drew & Glick, 1990; Stewart & Vezina, 1989; Vezina 
& Stewart, 1989). This further supports the view that the DI subfamily, not the D2 
subfamily, is critical in the development of behavioral sensitization to both direct and 
indirect dopamine agonists. 
In addition to the administration of selective antagonists, the chronic 
administration of selective agonists has also been used to assess the role of the 
specific dopamine receptor subtypes. To further assess the role of the dopamine DI 
receptor subfamily, SKF 38393, a direct DI-type dopamine agonist has been 
investigated. Acutely, SKF 38393 inhibits locomotor activity in a dose dependent 
manner and this inhibition does not change with chronic treatments (Mattingly, 
Rowlett, & Lovell, 1993). However, rats chronically pretreated with SKF 38393 
display a sensitized response to a subsequent challenge injection of the direct DI/DZ 
agonist apomorphine (Mattingly et al., 1993). Thus, repeated stimulation ofDl-type 
receptor subfamily appears to be sufficient for the development of behavioral 
sensitization. 
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In contrast to the previous findings which suggest that the DI-type receptor 
subfamily, but not the DZ-type receptor subfamily, is critical in the development of 
behavioral sensitization, recent evidence suggests that DZ-type receptor subfamily 
may also contribute to the development of behavioral sensitization (Hoffman & Wise, 
1992; Hoffman & Wise, 1993; Wise & Carlezon, 1994). The role of the DZ 
subfamily has been evaluated using selective DZ-type dopamine receptor agonists 
such as, bromocriptine and quinpirole. Following acute administrations, both of these 
drugs produce a marked inhibition in the locomotor response, but with repeated 
treatments both result in the development of behavioral sensitization (Hoffman & 
Wise, 1992; Wise & Carlezon, 1994; Willner, Papp, Cheeta, & Muscat, 1992; 
Mattingly et al., 1993). Moreover, bromocriptine induced sensitization displays 
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cross-sensitization with quinpirole (Hoffman & Wise, 1993). In addition, animals 
pretreated with quinpirole display a cross-sensitized response to apomorphine 
(Mattingly et al., 1993; Szechtman, Talangabayan, & Eilam, 1993). As expected, the 
co-administration of the D2 antagonist, raclopride, blocked the development of 
behavioral sensitization to bromocriptine (Wise & Carlezon, 1994). Surprisingly, 
bromocriptine- or quinpirole-induced sensitization can be prevented with the co-
administration of the selective DI-type antagonist, SCH 23390 (Wise & Carlezon, 
1994; Mattingly et al., 1993). Consequently, DI-type dopamine receptor stimulation 
appears to be necessary for the development of behavioral sensitization to D2-type 
agonists. Taken together, these findings suggest that DI-type receptor subfamily 
stimulation is critical to the development of behavioral sensitization, but D2-type 
receptor subfamily stimulation may also contribute to this effect (Mattingly et al., 
1993). 
It has been suggested D2-type dopamine agonists may result in the 
development of behavioral sensitization indirectly by producing autoreceptor 
subsensitivity (Rowlett, Mattingly, & Bardo, 1993; Mattingly, Fields, Langfels, 
Rowlett, Robinet, & Bardo, 1996). Autoreceptor subsensitivity has been proposed as 
an initial event in the cellular cascade associated with the development of behavioral 
sensitization to psychomotor stimulants (Henry et al., 1989; Wolf, White, Nassar, 
Brooderson, Khansa, 1993). According to thi~ hypothesis, sensitization may involve 
at least two cellular alterations in the mesocorticolimbic dopamine system: an initial 
and transient decrease in the sensitivity of the D2-type autoreceptors followed by a 
long lasting increase in the sensitivity of the Dl-type post-synaptic receptors. Thus, 
repeated quinpirole, or bromocriptine, treatments may directly result in autoreceptor 
subsensitivity, which may directly increase DI-type receptor stimulation via 
increased basal dopamine synthesis and release (Rowlett et al., 1993; Rowlett, 
Mattingly, & Bardo; 1995; Mattingly et al., 1996). Consistent with this hypothesis, 
both D 1-type and D2-type dopamine antagonists prevent the development of 
behavioral sensitization to the D2-type agonists, bromocriptine (Wise & Carlezon, 
1994) and quinpirole, as measured after an apomorphine challenge injection 
(Mattingly et al., 1993). 
IV. Dopamine D3 Receptors in the Development of Behavioral Sensitization. 
As mentioned previously, research has indicated that there are three receptor 
subtypes (D2, D3, and D4) within the D2-type subfamily (Lui et al., 1994). Sokoloff 
and colleagues first characterized the dopamine D3 receptor subtype and found it to 
be structurally similar to dopamine D2 receptors (Sokoloff, Giros, Martres, 
Bouthenet, & Schwartz, 1990). Studies to date indicate that the D3 receptor is 
localized preferentially in the limbic brain areas. Due to this localization, D3 
receptors have been considered as a therapeutic target in the treatment of drug 
addiction (Gilbert, Millar, & Cooper, 1995; Schwartz, Sokoloff, Giros, Martres, & 
Bouthenet, 1991, Shafer & Levant, 1998). 
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Although it is clear that dopamine D2-type receptors play a role in the 
development of behavioral sensitization, attempts to study the involvement of specific 
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receptor subtypes within the D2 subfamily have been hampered by the absence of 
sufficiently selective compounds. Bromocriptine, for example, is generally 
considered to be a selective dopamine D2 agonist, but it has less than a 2-fold higher 
affinity for dopamine D2 subtype receptors than D3 subtype receptors (Schwartz et 
al., 1992; Sokoloff, Giros, Martres, Andrieux, Besancon, Pilon, Bouthenet, Souil, & 
Schwartz, 1992). Similarly, although quinpirole has approximately a 100-fold greater 
affinity for dopamine D3 subtype receptors than D2 subtype receptors, its affinity for 
dopamine D4 receptors is only slightly lower than its affinity for D3 receptors 
(Levesque, Diaz, Pilon, Martres, Giros, Souil, Schoot, Morgat, Schwartz, & Sokoloff, 
1992; Sokoloff et al., 1992). Consequently, bromocriptine and quinpirole, probably 
stimulate more than one receptor subtype within the D2 subfamily. 
Recently, a putative selective dopamine D3 agonist, 7-hydroxy-2-(N,N-di-n-
propylamino )tetralin (7-OH-DPAT) has been identified. This compound has been 
reported to have a 100- and 1000- fold greater affinity for dopamine D3 subtype than 
D2 and D4 receptors subtypes, respectively (Levesque et al., 1992). 
Recent research using 7-OH-DPAT suggests that stimulation of the dopamine 
D3 receptor subtype produces behavioral and neurochemical effects similar to those 
of other D2-type agonists. For example, like bromocriptine and quinpirole, the acute 
administration of7-OH-DPAT produces a biphasic effect on locomotor activity with 
a period of locomotor inhibition being followed by a period of weak locomotor 
stimulation (Mattingly et al., 1996a). The acute inhibition of activity produced by 7-
OH-DPAT appears to be related to autoreceptor stimulation in that dopamine 
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synthesis and release are decreased following the acute administration of7-0H-
DPAT (Mattingly et al., 1996a). Further the chronic administration of7-0H-DPAT 
has recently been found to result in behavioral sensitization with repeated 
administration in manner similar to that ofbromocriptine and quinpirole (Mattingly et 
al., 1996a). Despite these similarities, a number of differences have been observed 
among the behavioral and neurochemical effects of7-0H-DPAT and other D2-type 
dopamine agonists. For example, the repeated administration of quinpirole results in 
an increase in basal dopamine synthesis, presumably due to the development of 
autoreceptor subsensitivity (Rowlett et al., 1995). As noted previously, autoreceptor 
subsensitivity has been suggested to be the primary mechanism by which quinpirole 
induces behavioral sensitization. Although, 7-0H-DPAT treatments produce 
sensitization similar to quinpirole, repeated 7-0H-DPAT treatments do not affect 
basal dopamine synthesis (Mattingly et al., 1996a). The latter finding suggests that 
repeated 7-0H-DPAT treatment does not result in the development of autoreceptor 
subsensitivity. Moreover, rats sensitized to quinpirole display cross-sensitization to 
both apomorphine (Mattingly et al., 1993) and cocaine (Szechtman et al., 1993; 
Horger & Schenk, 1991). In contrast, rats sensitized to 7-0H-DPAT do not display 
cross-sensitization to either apomorphine or cocaine (Mattingly et al., 1996a). These 
behavioral and neurochemical discrepancies suggest that the similar acute and chronic 
behavioral effects of7-0H-DPAT and other P;!-type agonists such as quinpirole may 
not be mediated by the same neurochemical mechanisms. 
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V. Purpose of the Present Study 
In summary, the development of behavioral sensitization to dopamine D2-type 
agonists, such as quinpirole and bromocriptine, appears to be mediated by an indirect 
increase in dopamine D 1 subfamily receptor stimulation due to the development of 
autoreceptor subsensitivity (Mattingly et al., 1993; Szechtman et al., 1993; Horger & 
Schenk, 1991). Consistent with this view, both Dl- and D2-type dopamine 
antagonists are effective in preventing the development of behavioral sensitization to 
D2-type agonists. Although, chronic 7-OH-DPAT treatments induce behavioral 
sensitization, repeated 7-OH-DPAT treatments do not result in the autoreceptor 
subsensitivity. Thus, increased Dl subfamily receptor stimulation may not be 
involved in the development ofbehavioral sensitization to 7-OH-DPAT. The purpose 
of the present study, therefore, was to determine whether concurrent treatments with 
the selective Dl subfamily dopamine antagonist, SCH 23390, would prevent the 
development ofbehavioral sensitization to 7-OH-DPAT. IfDl-type receptor 
stimulation is important, then concurrent SCH 23390 treatments should block the 
development ofbehavioral sensitization to 7-OH-DPAT. 
Subjects 
CHAPTER2 
METHODS 
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Thirty-two male Wistar albino rats (Harlan Industries, Indianapolis, IN) 
weighing between 250-300 g at the beginning of the experiment served as subjects. 
The rats were individually housed in hanging wire-mesh cages in a colony room. The 
room was maintained on a 12-hour light dark cycle, and all behavioral testing took 
place during the light phase of the cycle. Food and water were available continuously. 
Apparatus 
Behavioral testing was taken in four open field chambers (see Figure 1, Med 
Associates model OFA-163), and each chamber was located in an individual sound 
attenuated experimental cubicle. 
Figure 1: Med-Associates locomotor activity testing chambers. 
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Each chamber was equipped with a 16 X 16 array of photocell beams placed 2.5 cm 
above the floor. A clear acrylic cylinder ( 41 cm in diameter) was placed inside the 
square chamber. The photocell beams were connected to a Gateway 2000 computer in 
the next room. Using Med-Associates software, distance traveled (cm), number of 
rears, and stereotypy counts (small movements) were recorded in 20 min intervals. 
(±)-7-hydroxy-dipropylaminotetralin hydrobromide (7-OH-DPAT; Research 
Biomedicals), and R(+)-SCH 23390 (Research Biomedicals) were dissolved in 
distilled water and injected subcutaneously in a volume of 1.0 ml/kg. Doses of each 
drug were calculated based upon the salt form of the drug. Vehicle injections were 
given using the same route and volume as the corresponding drug injection. 
Design and Procedure 
At the beginning of the experiment, all rats were randomly assigned to one of 
four treatment groups of a two (SCH 23390 dose: 0 or 0.1 mg/kg) X two (7-OH-
DPAT dose: 0 or 1.0 mg/kg) factorial design (see below, Table 1). 
Table 1 
Experimental Design 
First Injection 
SC 
VEIDCLE 
SCH23390 
Second Injection (sc) 
VEIDCLE 7-OH-DPAT 
N=8 
N=8 
N=8 
N=8 
A summary of the counterbalancing procedure is depicted in Appendix B, Table 14. 
14 
The experiment was conducted in two phases: the pretreatment phase and the 
sensitization test. Prior to each of the seven pretreatment sessions, the rats were first 
injected with vehicle or SCH 23390 (0.1 mg/kg sc) followed 15 min later by an 
injection of either vehicle or 7-0H-DPAT (1.0 mg/kg sc). Fifteen min following the 
second injection, the rats were placed in the activity chambers for 120 min and tested 
for locomotor activity. Prior to session eight (sensitization test) all rats were first 
given an injection (sc) of vehicle, followed 15 min later by a 1.0 mg/kg injection (sc) 
of7-0H-DPAT. Fifteen min following the 7-0H-DPAT injection all animals were 
placed in the activity chambers for 120 min. Animals were immediately returned to 
the homecage after each of the two injections prior to behavioral testing. All activity 
sessions were separated by a 48 hr drug free withdrawal interval. 
Data Analysis 
Significant differences among the groups in mean distance traveled, rears, and 
stereotypy during the pretreatment phase were analyzed using mixed four factor 
analyses of variance (ANOV As) using drug treatment conditions as between factors, 
and test session, and blocks of 20 min within sessions, as repeated measures. 
Significant interactions were analyzed with additional ANOV As performed on 
individual session and/or block data, followed by Newman-Keuls post hoc tests. 
Mean distance traveled, rears, and stereotypic counts of the groups on the 
sensitization test were analyzed using mixed tp.ree factor ANOV As. 
Pretreatment Sessions - Days 1-7 
Distance Traveled: 
CHAPTER3 
RESULTS 
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The mean distance traveled by the four groups across the six 20 min blocks of 
sessions 1,4, and, 7 is presented in Figure 2. A summary of the ANOVA performed 
on all seven sessions is presented in Table 2 (see Appendix A). As may be seen in 
Figure 2, repeated treatments with 7-OH-DPAT produced a progressive increase in 
distance traveled across both sessions and blocks of 20 min within each session. [7-
OH-DP AT effect: E(l, 28) = 17.58, Jl < .0001; 7-OH-DPAT x Session interaction: 
E(6, 168) = 5.06, JL < .0001; 7-OH-DPAT x Block interaction: E(5, 140) = 22.19, JL < 
.0001, 7-OH-DPAT x Session x Block interaction: E(30, 840) = 4.45, ll < .0001]. 
Overall, repeated SCH 23390 treatments significantly suppressed locomotor activity 
[antagonist effect: E(l, 28) = 82.49, Jl < .0001] and this suppression did not 
significantly change over sessions or blocks within each session [ Antagonist x 
Session interaction: E < 1.00; Antagonist x Block interaction: E(5, 140) = 2.17, ll > 
.05]. However, animals pretreated with SCH 23390 and 7-OH-DPAT did display an 
increase in distance traveled across some of the blocks, which increased across 
sessions [Antagonist x 7-OH-DPAT x Block interaction: E(5, 140) = 15.04, Jl < 
.0001; Antagonist x Session x Block interaction: E(30, 840) = 2.17, ll < .001; 
Antagonist x 7-OH-DPAT x Session x Block interaction: E(30, 840) = 2.00, ll < .01]. 
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Subsequent analysis of individual block data on Session 7 using ANOV As followed 
by Newman-Keuls post-hoc test indicated that animals pretreated with 7-OH-DPAT 
(VEH-DPAT) were significantly more active across all blocks than the vehicle 
control animals (VEH-VEH) [11s < .05] (see Appendix A, Table 8 for ANOV A 
summary). In contrast, rats treated with both SCH 23390 and 7-OH-DPAT (SCH-
DPAT) did not differ significantly from the vehicle control group (VEH-VEH) on any 
block [11s > .05]. Therefore, concurrent treatments with SCH 23390 effectively 
blocked the acute locomotor-activating effects of7-OH-DPAT over sessions. 
Rears: 
The mean number of rears for the four treatment groups across the six 20 min 
blocks of sessions 1,4, and 7 is presented in Figure 3. A summary of the ANOVA 
performed on the seven sessions is presented in Table 3 (see Appendix A). Overall, 
7-OH-DPAT treatments significantly increased rearing behaviors during the 
pretreatment sessions [7-OH-DPAT effect: E(l, 28) = 29.58, I1 < .0001] and SCH 
23390 treatments significantly suppressed rearing behavior [antagonist effect: 
E(l, 28) = 27.54, I1 < .0001]. More important, the stimulating effects of7-OH-DPAT 
on rearing behaviors were blocked by concurrent treatments with SCH 23 3 90 
[Antagonist x 7-OH-DPAT interaction: E(l, 28) = 9.43, I1 < .05]. However, the effects 
of both SCH 23390 and 7-OH-DPAT treatments varied across sessions and blocks 
within sessions. 
As may be seen in Figure 3, 7-OH-DPAT produced a biphasic effect on 
rearing behaviors during session 1, with an initial suppression, followed by a 
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progressive increase in rearing across blocks. Additionally, across sessions, the initial 
inhibitory effects of7-0H-DPAT decreased, and the stimulating effects progressively 
increased [7-0H-DPAT x Session interaction: E(6, 168) = 9.49, Jl < .0001; 7-0H-
DPAT x Block interaction: E(5, 140) = 56.63, Jl < .0001; 7-0H-DPAT x Session x 
Block interaction: E(30, 840) = 5.15, Jl < .0001]. 
In contrast, SCH 23390 suppressed rearing on the initial blocks of session 1, 
but this suppression diminished as the rearing behavior of the vehicle control animals 
decreased across blocks. [Antagonist x Block interaction: E(5, 140) = 3.85, ll < .05]. 
Similarly, the initial suppression of rears produced by SCH 23390 decreased across 
sessions as the number of rears exhibited by the vehicle control animals progressively 
decreased [Antagonist x Session x Block interaction: l:(30, 840) = 3.20, Jl < .0001]. 
The progressive stimulating effects of7-0H-DPAT on rearing behavior were 
significantly reduced by concurrent treatments with SCH 23390 [Antagonist x 7-0H-
DPAT x Block interaction: E(5, 140) = 31.55, Jl < .0001; Antagonist x 7-0H-DPAT x 
Session x Block interaction: E(30, 840) = 2.38, Jl < .0001]. Subsequent analysis of 
individual block data on session 7 using ANOV As followed by Newman-Keuls post-
hoc tests indicated that animals treated with 7-0H-DPAT alone (VEH-DPAT) were 
significantly greater than vehicle control animals (VEH-VEH) on all blocks except 
block 1 (see Appendix A for ANOV A summary, Table 9). In contrast, animals treated 
with SCH 23390 and 7-0H-DPAT were not significantly different from vehicle 
control animals on blocks 2-6. Therefore, concurrent treatments with SCH 23390 
effectively blocked the acute rearing behavior of7-0H-DPAT over sessions. 
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Stereotypy: 
Figure 4 displays the mean stereotypic counts for the four pretreatment groups 
during sessions 1,4, and 7. A summary of the ANOVA performed on the seven 
sessions is presented in Table 4 (Appendix A). As may be seen in Figure 4, similar to 
the distance traveled and rearing results, 7-OH-DPAT produced an overall increase in 
stereotypic counts during the pretreatment sessions [7-OH-DPAT effect: E(l, 28) = 
224.79, Q < .0001] and SCH 23390 significantly suppressed stereotypic behaviors 
[antagonist effect: E(l, 28) = 165.96, Q < .0001]. Moreover, concurrent SCH 23390 
treatments completely blocked the acute locomotor activating effects of7-OH-DPAT 
[antagonist x 7-OH-DPAT interaction: E(l, 28) = 68.77, Q <.0001]. Indeed, the 
Newman-Keuls post-hoc test on this interaction indicated that 7-OH-DPAT alone 
significantly increased stereotypic behaviors versus the vehicle control animals. In 
addition, animals treated concurrently with SCH 23390 and 7-OH-DPAT did not 
differ significantly from the vehicle control animals (Qs < .05). 
Repeated treatments with 7-OH-DPAT did produce an increase in stereotypy 
across blocks while vehicle animals displayed a decrease in stereotypic counts across 
blocks [7-OH-DPAT x Block interaction: E(5, 140) = 29.90, IL< .0001]. In addition, 
across all sessions, animals treated with 7-OH-DPAT alone were significantly more 
active than the vehicle group [7-OH-DPAT x Session interaction: E(6, 168) = 2.18, Q 
< .05]. Although the pattern of activity for the 7-OH-DPAT animals changed over 
sessions and blocks within sessions, the mean activity for these animals did not 
significantly change over the pretreatment phase. In contrast, the stereotypic activity 
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for vehicle animals decreased across sessions and blocks within sessions, presumably 
due to habituation. [7-OH-DPAT x Session x Block interaction: E(30, 840) = 2.42, I! 
<.0001]. 
Animals treated with SCH 233 90 did not display any change in suppression of 
stereotypic counts across blocks, although the vehicle groups did show a decrease in 
stereotypic counts across blocks [Antagonist x Block interaction: E(5, 140) = 4.31, I! 
< . 001]. Also, there was no change in stereotypic counts across sessions for animals 
treated with SCH 23390 [Antagonist x Session interaction: E(6, 168) = 1.13, I!,> .05; 
Antagonist x Session x Block interaction: E(30, 840) = 1.42, I!> .05]. Stereotypic 
behaviors increased with repeated 7-OH-DPAT treatments alone compared to the 
progressive decrease in stereotypic counts of the vehicle control animals across 
blocks [Antagonist x 7-OH-DPAT x Block interaction: E(5, 140) = 29.83, I!< .0001]. 
Individual block ANOVAs for Session 7 followed by Newman-Keuls post-hoc tests 
indicated that there were significant differences between the SCH 23390-DPAT and 
vehicle-vehicle groups on blocks 2, 3, and 6 due to a progressive decrease in the 
stereotypic counts of the vehicle control group (ns <.05) (see Appendix A for 
ANOVA summary, Table 10). In spite of the fact that overall concurrent treatments 
with SCH 23390 effectively blocked the acute locomotor-activating effects of7-OH-
DPAT, this finding is not supported by the block analysis. Therefore, SCH 23390 did 
not effectively block 7-OH-DPAT induced stereotypic behavior. 
Sensitization Test Session 8 
Distance Traveled: 
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Figure 5 displays the mean distance traveled for the four pretreatment groups 
after a 1.0 mg/kg dose of7-OH-DPAT. A summary of the ANOVA performed on 
this data is presented in Table 5 (see Appendix A). Overall, as may be seen in the left 
panel, prior treatment with 7-OH-DPAT significantly increased subsequent 
behavioral sensitivity to the activating effects of the 7-OH-DPAT challenge injection 
[7-OH-DPAT effect: E(l, 28) = 16.94, g <.001]. More important, prior treatments 
with SCH 23390 alone did not significantly increase subsequent sensitivity to 7-OH-
DPAT, and the concurrent treatments of SCH 23390 and 7-OH-DPAT did not block 
the overall development of sensitization to 7-OH-DPAT [antagonist effect: E < 1.00; 
Antagonist x 7-OH-DPAT interaction: E < 1.00]. However, as shown on the right 
panel, concurrent treatment with SCH 23390 and 7-OH-DPAT did appear to decrease 
sensitivity to 7-OH-DPAT across blocks. That is, although all groups tended to 
increase activity across blocks, the rats pretreated with 7-OH-DPAT alone displayed 
an increase in distance traveled across all six time blocks, whereas for rats treated 
with both SCH 23390 and 7-OH-DPAT, activity declined after block 4 [block effect: 
E(5, 140) = 17.31, g < .0001; Antagonist x 7-OH-DPAT x Block interaction: I'.(5,140) 
= 2. 71, g < . 05]. Subsequent analysis of individual block data indicated that the 7-
OH-DP AT pretreatment group (VEH-DPAT) was significantly more active than the 
vehicle control group (VEH-VEH) on block 6 (g < .05), but the activity of the other 
two groups did not significantly differ from the vehicle control group (g <. 05) 
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(see Appendix A for ANOVA summary, Table 11). Thus, the development of 
behavioral sensitization to 7-0H-DPAT appeared to be at least partially attenuated by 
concurrent SCH 23390 treatments. 
Rears: 
Figure 6 displays the mean number of rears for the four pretreatment groups 
after a 1.0 mg/kg dose of7-0H-DPAT. A summary of the ANOVA performed on 
this data is presented in Table 6 (see Appendix A). As may be seen in the left panel, 
pretreatment with 7-0H-DPAT significantly increased subsequent sensitivity to a 
challenge injection of7-0H-DPAT [7-0H-DPAT effect: E(l, 28) = 10.38, n < .05]. 
Further, it can be seen that pretreatment with SCH 23390 did not significantly 
increase the subsequent sensitivity to the challenge injection of7-0H-DPAT 
[antagonist effect: E(l, 28) = 3.54, n > .05]. More important, concurrent pretreatment 
with SCH 23390 and 7-0H-DPAT did not block the overall development of 
behavioral sensitization to 7-0H-DPAT [Antagonist x 7-0H-DPAT interaction: E < 
1.00]. However, as shown on the right panel, concurrent treatment with SCH 23390 
and 7-0H-DPAT did appear to decrease sensitivity to 7-0H-DPAT across blocks. 
That is, although all groups tended to increase activity across blocks, the rats 
pretreated with 7-0H-DPAT alone displayed an increase in distance traveled across 
blocks, whereas rats pretreated with both SCH 23390 and 7-0H-DPAT, activity 
declined after block 5 [block effect: .E(5, 140) = 40.25, n < .0001; 7-0H-DPAT x 
Block interaction: E(5, 140) = 11.26, n < .0001]. Antagonist x 7-0H-DPAT x Block 
interaction: E(5, 140) = 3.99, n < .05]. Subsequent ANOVAs and 
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Newman Keuls post-hoc tests on individual block data indicated that the 7-OH-DPAT 
pretreatment group was significantly more active than the vehicle control group on 
the first, fifth, and sixth block (R < .05) (see Appendix A for ANOVA summary, 
Table 12). Although, the mean number of rears for the other two pretreatment groups 
did not differ significantly from the vehicle control group on any block (,Rs < .05). 
Thus, pretreatment with SCH 23390 partially attenuated the development of 
behavioral sensitization to 7-OH-DPAT as measured by rearing behavior. 
Stereotypy: 
Figure 7 displays the mean number of stereotypic counts for the four 
pretreatment groups after a 1.0 mg/kg dose of7-OH-DPAT. A summary of the 
ANOV A performed on this data is presented in Table 7 (see Appendix A). As may 
be seen in the left panel, pretreatment with 7-OH-DPAT and/or SCH 23390 did not 
significantly affect subsequent sensitivity to a challenge injection of7-OH-DPAT 
[7-OH-DPAT effect: E(l, 28) = 3.31, R > .05; antagonist effect: E < 1.00; antagonist x 
7-OH-DPAT interaction: E(l, 28) = 2.66, p > .05]. Although stereotypic counts 
increased across blocks [block effect: E(5, 140) = 12.04, p < .0001], the increase did 
not vary across the pretreatment groups [antagonist x block interaction: E(5, 140) = 
1.57, p > .05; 7-OH-DPAT x block interaction: E(5,140) = 1.87, p > .05; antagonist x 
7-OH-DPAT x block interaction: E(5, 140) = 1.61, p > .05]. Thus, pretreatment 
with 7-OH-DPAT did not result in behavioral sensitization with stereotypic counts as 
a behavioral measure. 
7-0H-DPAT CHALLENGE TEST 
~ 30000 
:::) 
8 25000 
~ g: 20000 
0 
~ 15000 
ILi 
t-
; 10000 
~ 5000 
o,..__.,___..__ 
120 MIN TEST SESSION 
VEH•VEH VEH-DPAT SCH-VEH SCH-DPAT 
PRETREATMENT CONDITION 
Pretreatment Cond ion 
7000 -0- VEHICLE-VEHICLE 
.,._ VEHICLE-DPAT(1,0) 
6000 •D- SCH(0.1)-VEHICLE -
-• SCH(0.1)-DPAT(1,0) ............ . 
5000 _;§••" •• ••• 
•• 
•• 
• 
4000 
3000 
2000 
1000 
o-~1-----2----~3-----4--s..__-_ ... 6___. 
BLOCKS OF 20 MIN 
Eigure 7· Mean stereotypic counts(± SEM) after a 1,0 mg/kg 7-0H-DPAT (DPAT) challenge injection 
(session 8) for rats previously treated subchronically with either vehicle (VEH) or SCH 23390 (0.1 mg/kg SCH) 
ih combination with either vehicle (VEH) or 7-0H-DPAT (1.0 mg/kg DPAT)- The left panel represents the 
total session activity and the right panel presents the same data as a function of six 20 min blocks within the 
session. · 
N 
00 
CHAPTER4 
DISCUSSION 
I. Behavioral Sensitization to 7-0H-DPAT: 
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Behavioral sensitization is commonly characterized by a progressive increase 
in a behavioral response after repeated administration of the same dose of a drug. 
Many behavioral responses sensitize to the effects of psychostimulant drugs. In the 
current experiment, total distance traveled ( cm), stereotypic counts, and rears were 
used to measure behavioral sensitization to the putative dopamine D3 agonist, 
7-0H-DPAT. As discussed previously, the current results indicate that repeated 
administration of7-0H-DPAT alone produced a significant augmentation in total 
distance traveled over the pretreatment sessions. Consistent with this finding, rats 
previously treated with 7-0H-DPAT were significantly more active following the 7-
0H-DPAT challenge injection than rats receiving 7-0H-DPAT for the first time. 
These findings are consistent with previous studies demonstrating the development of 
behavioral sensitization to 7-0H-DPAT (Mattingly, Himmler, Bonta, & Rice, 1998, 
Mattingly et al., 1996a). 
The mean number of rears progressively increased over the pretreatment 
sessions, although this effect was not as robust as total distance traveled. Likewise, 
on the challenge test, sensitization was only apparent in the last 40 min of the session 
using rearing as a behavioral measure. In contrast to distance traveled and rears, 
mean stereotypic counts did not significantly increase over pretreatment sessions or 
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on the challenge test. This is consistent with other studies, in that other 
psychostimulant drugs often do not produce sensitization when using stereotypic 
counts as a behavioral measure. For example, locomotor activity, but not stereotypy, 
sensitized to repeated administrations ofapomorphine (Mattingly et al., 1988). White 
(1996) has suggested that horizontal and vertical locomotion produced by dopamine 
agonists is mediated by increased stimulation of the mesolimbic dopamine pathway. 
Whereas, stereotypic responses induced by dopamine agonists are mediated by 
increased stimulation of dopamine receptors in the nigrostriatal dopamine pathway. If 
this view is correct, then the current findings suggest that behavioral sensitization 
involves the mesolimbic dopamine pathway. 
II. Effects of Dopamine Antagonists: 
As would be expected, recent research indicates that the concurrent treatment 
with the dopamine D2/D3 receptor antagonist eticlopride blocks the acute locomotor 
activating effects of7-OH-DPAT, and completely prevents the development of 
behavioral sensitization (Mattingly et al., 1998). Although this finding confirms that 
the development of sensitization to 7-OH-DPAT is related to the repeated stimulation 
of the dopamine DZ-type receptors, whether the effectiveness of eticlopride was due 
to blocking D2 or D3 receptors, or both, cannot be determined. 
Like eticlopride, the dopamine DI-type antagonist SCH 23390 suppressed 
locomotor activity in the current study and blocked the acute locomotor activating 
effects of7-OH-DPAT. However, unlike eticlopride, concurrent SCH 23390 
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treatments did not completely prevent the development of behavioral sensitization to 
7-OH-DPAT. Indeed, the SCH 23390/7-OH-DPAT group did not significantly differ 
from the vehicle/7-OH-DPAT group in total distance traveled during the two-hour 7-
OH-DPAT-challenge test. However, the SCH 23390/7-OH-DPAT group was 
significantly less active than the vehicle/7-OH-DPAT on the last twenty minute block 
of the challenge test session. Thus, this dose of SCH 23390 appeared to have at least 
partially attenuated the development of sensitization to 7-OH-DPAT. 
As noted earlier, previous research has suggested that some minimal level of 
dopamine DI-type receptor stimulation is necessary for the development of 
behavioral sensitization to dopamine D2-type agonists. Consistent with this view, 
Wise and Carlezon (1994), using a design similar to that used in the present 
experiment, found that concurrent treatments with 0.1 mg/kg SCH 23390 completely 
blocked the development of locomotor sensitization to the D2-type dopamine agonist, 
bromocriptine, as measured after a bromocriptine challenge injection. Similarly, 
Mattingly and colleagues (1993) found that a high dose of SCH 23390 (0.5 mg/kg) 
completely blocked the acute locomotor activating effects of repeated treatments with 
the D2/D3 dopamine agonist, quinpirole, and subsequent cross-sensitization to the 
nonselective dopamine agonist, apomorphine. Together with the present results, these 
findings suggest that the development of sensitization to 7-OH-DPAT, bromocriptine, 
and quinpirole may not be mediated by entirely common neurochemical mechanisms. 
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III. DI-Type Receptors, Autoreceptors, and Sensitization: 
As previously discussed, autoreceptor subsensitivity has been associated with 
the development of behavioral sensitization to psychomotor stimulants. (see Henry et 
al., 1989; Wolf et al., 1993). The development of behavioral sensitization may 
involve two cellular changes: an initial and transient decrease in the sensitivity of the 
D2-type autoreceptors followed by a long-lasting increase in the sensitivity of the DI-
type post-synaptic receptors. Therefore, chronic treatments with bromocriptine and 
quinpirole may directly result in autoreceptor subsensitivity, which may indirectly 
increase DI-type receptor stimulation via increased basal dopamine synthesis and 
release (Rowlett et al., 1993, 1995; Mattingly et al., 1996). Consistent with this 
hypothesis, both DI-type and D2-type dopamine antagonists prevent the development 
of behavioral sensitization to the D2-type antagonist, bromocriptine and quinpirole 
(Mattingly et al., 1993; Wise & Carlezon, 1994). However, as noted previously, 
although repeated quinpirole treatments result in an increase in basal dopamine 
synthesis, consistent with the autoreceptor subsensitivity, repeated 7-0H-DPAT 
treatments do not affect basal dopamine synthesis (Mattingly et al., 1996). This 
finding, of course, suggests that autoreceptor subsensitivity is not involved in the 
development of behavioral sensitization to 7-0H-DPAT. Moreover, in the absence of 
autoreceptor subsensitivity, repeated 7-0H-DPAT treatments should not result in an 
increase in DI-type receptor stimulation. Consequently, concurrent treatments with 
DI-type receptor antagonists would not be expected to block the development of 
behavioral sensitization to 7-0H-DPAT. Thus, the inability of the DI-type antagonist 
SCH 23390 to block the development of sensitization may be consistent with the 
finding that repeated 7-OH-DPAT treatments do not increase basal dopamine 
synthesis (Mattingly et al., 1996). 
IV. D3-Receptors and Behavioral Sensitization to Cocaine: 
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As discussed previously, a great deal of evidence suggests the involvement of 
dopamine DI-type receptors in the development and persistent of behavioral 
sensitization to both selective and nonselective dopamine agonists (see Stewart & 
Badiani, 1993; Rowlett et al., 1995). Consistent with this view, the Dl-type receptor 
antagonist SCH 23390 has been reported to block the development of sensitization to 
the nonselective dopamine agonists, apomorphine and amphetamine (Stewart & 
Vezina, 1989; Vezina & Stewart, 1989; Drew & Glick, 1990; Mattingly et al., 1991), 
as well as the selective D2-type agonists, bromocriptine and quinpirole (Mattingly et 
al., 1993; Wise & Carlezon, 1994). Curiously, the development of behavioral 
sensitization to cocaine, like 7-OH-DPAT, is not blocked by concurrent treatments 
with SCH 23390 (Kurihara & Uchihashi, 1993; Mattingly et al., 1994; 1996b). 
Moreover, behavioral sensitivity to cocaine, like 7-OH-DPAT is increased following 
brief repeated treatments with SCH 23390 (4 days) alone (Mattingly et al., 1996b; 
1998). In contrast, sensitivity to apomorphine, amphetamine, and bromocriptine is 
not affected by prior SCH 23390 treatments (Vezina & Stewart, 1989; Mattingly et 
al., 1991; Mattingly et al., 1993; Wise & Carlezon, 1994). These similarities suggest 
that the development of sensitization to cocaine and 7-OH-DPAT may be mediated 
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by some common neurochemical mechanisms. However, as noted previously, cross-
sensitization to cocaine is not observed following repeated 7-0H-DPAT treatments 
(Mattingly et al., 1996a). 
IV. Summary and Conclusions: 
Although 7-0H-DPAT is often considered a selective dopamine D3 receptor 
agonist, recent research suggests that the in vivo selectivity of 7-0H-DP AT for D3 
receptors, compared to D2 receptors, may be relatively small (Levesque, 1996). 
Consistent with the in vivo findings, the acute and chronic behavioral effects of 7-
0H-DP AT are, for the most part, similar to those of other prototypical dopamine D2-
type agonists (Mattingly et al., 1996a). The present results along with our previous 
findings, however, reveal a number of important neurochemical and ·behavioral 
differences between the effects of7-0H-DPAT and the D2-type agonists, 
bromocriptine and quinpirole. Although, the basis for these differences is currently 
unknown, these differences clearly indicate that the development of behavioral 
sensitization to dopamine D2-type agonists is not mediated by a common unitary 
neurochemical mechanism. 
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APPENDIX A 
ANOVA SUMMARY TABLES 
40 
41 
Table 2 
Summary of Analysis of Variance Performed on Mean 
Distance Traveled: Pretreatment Sessions 1-7 
Source Df MS F nu 
Between Groups 
Antagonist (A) 1 8.886 E+08 82.49*** .75 
7-OH-DPAT (D) 1 1.374 E+09 17.58*** .39 
AxD 1 6.501 E+08 60.35*** .68 
Error 28 1.077 E+07 
Within Groups 
Session (S) 6 10797923 4.41 ** .14 
AxS 6 2176131 0.89 
DxS 6 12387398 5.06*** .15 
AxDxS 6 1903501 0.78 
Error 168 2.448 E+06 
Block (B) 5 5213774 5.16** .16 
AxB 5 2191804 2.17 
DxB 5 22414160 22.19*** .44 
AxDxB 5 15196326 15.04*** .35 
Error 140 1.010E+06 
SxB 30 2014561 4.12*** .13 
AxSxB 30 1060412 2.17** .07 
DxSxB 30 1687438 4.45*** .14 
AxDxSxB 30 980365 2.00** .07 
Error 840 4.892E+05 
***g.0001 
**11 .001 
42 
Table 3 
Summary of Analysis of Variance Performed on Mean 
Number of Rears: Pretreatment Sessions 1-7 
Source df MS F nu 
Between Groups 
Antagonist (A) 1 447672.50 27.54*** .50 
7-OH-DPAT (D) 1 480748.19 29.58*** .51 
AxD 1 153322.94 9.43* .25 
Error 28 16254.27 
Within Groups 
Session (S) 6 16242.22 6.44*** .19 
AxS 6 4966.39 1.97 
DxS 6 23915. 18 9.49*** .25 
AxDxS 6 5235.98 2 . .08 
Error 168 2521.20 
Block (B) 5 23353.28 18.81 *** .40 
AxB 5 4775.54 3.85* .12 
DxB 5 70323.76 56.63*** .67 
AxDxB 5 39175.51 31.55*** .53 
Error 140 1241.77 
SxB 30 4283.80 8.53*** .23 
AxSxB 30 1605.65 3.20*** .10 
DxSxB 30 2585.80 5.15*** .16 
AxDxSxB 30 1195.12 2.38*** .08 
Error 840 501.98 
***12 .0001 
*n.o5 
43 
Table 4 
Summary of Analysis of Variance Performed on Mean 
Stereotypic Counts: Pretreatment Sessions 1-7 
Source Df MS F nu 
Between Groups 
Antagonist (A) 1 1.145E+09 165.96*** .85 
7-OH-DPAT (D) 1 l.550E+09 224.79*** .89 
AxD 1 4.743E+08 68.77*** .71 
Error 28 6.897E+06 
Within Groups 
Session (S) 6 1406528 0.91 
AxS 6 1749427 1.13 
DxS 6 3372949 2.18* .07 
AxDxS 6 627687 0.41 
Error 168 l.546E+06 
Block (B) 5 3502645 3.93* .12 
AxB 5 3845138 4.31** .13 
DxB 5 26056826 29.90*** .51 
AxDxB 5 26618800 29.83*** .51 
Error 140 8.922E+05 
SxB 30 1957074 3.77*** .12 
AxSxB 30 739536 1.42 
DxSxB 30 1258623 2.42*** .08 
AxDxSxB 30 605163 1.17 
Error 840 5.192E+05 
***n.0001 
**n .001 
*n.05 
44 
Table 5 
Summary of Analysis of Variance Performed on Mean 
Distance Traveled: 7-OH-DPAT Challenge Day 8 
Source df MS F nu 
Between Groups 
Antagonist (A) 1 1824143 0.20 
7-OH-DPAT (D) 1 154335022 16.94** .38 
AxD 1 521115 0.06 
Error 28 9113136 
Within Groups 
Block (B) 5 25795878 17.31*** .38 
AxB 5 7027713 4.72** .14 
DxB 5 1513691 1.02 
AxDxB 5 4032209 2.71 * .09 
Error 140 1490148 
***g.0001 
**g.001 
*12...05 
45 
Table 6 
Summary of Analysis of Variance Performed on Mean 
Number of Rears: 7-OH-DPAT Challenge Day 8 
Source df MS F nu 
Between Groups 
Antagonist (A) 1 35916.02 3.54 
7-OH-DPAT (D) 1 105468.75 10.38* .21 
AxD 1 3888.00 0.38 
Error 28 10158.23 
Within Groups 
Block (B) 5 37912.10 40.25*** .59 
AxB 5 3787.92 4.02* .13 
DxB 5 10604.58 11.26*** .29 
AxDxB 5 3754.70 3.99* .12 
Error 140 941.88 
***u.0001 
*Jl....05 
46 
Table 7 
Summary of Analysis of Variance Performed on Mean 
Stereotypic Counts: 7-OH-DPAT Challenge Day 8 
Source df MS F nu 
Between Groups 
Antagonist (A) 1 1504500 0.29 
7-OH-DPAT (D) 1 17384558 3.31 
AxD 1 13973050 2.66 
Error 28 5254632 
Within Groups 
Block (B) 5 11951625 12.04*** .30 
AxB 5 1555213 1.57 
DxB 5 1856482 1.87 
AxDxB 5 1598243 1.61 
Error 140 992291 
***B.0001 
47 
Table 8 
Summary of Analysis of Variance Performed on Mean 
Distance Traveled: Pretreatment Session 7 Blocks 1-6 
Source df MS F nu 
Between Groups 
Block 1 
Antagonist (A) 1 10807937 58.96*** .68 
7-OH-DPAT (D) 1 2782706 15.18** .35 
AxD 1 1039534 5.67* .17 
Error 28 183324 
Block2 
Antagonist (A) 1 11647418 6.59* .19 
7-OH-DPAT (D) 1 30737524 17.38** .38 
AxD 1 9726795 5.50* .16 
Error 28 1768663 
Block 3 
Antagonist (A) 1 13114881 3.25 
7-OH-DPAT (D) 1 53981921 13.37** .32 
AxD 1 12166998 3.01 
Error 28 4038663 
Block4 
Antagonist (A) 1 23947871 7.71** .22 
7-OH-DPAT (D) 1 63307353 20.37*** .42 
AxD 1 22125284 7.12** .20 
Error 28 3107968 
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Table 8 ( continued) 
Source df MS F nu 
Between Groups 
Block 5 
Antagonist (A) 1 57269238 39.22*** .58 
7-OH-DPAT (D) 1 58097678 39.79*** .59 
AxD 1 51946229 35.57*** .56 
Error 28 1460210 
Block 6 
Antagonist (A) 1 41256099 25.36*** .48 
7-OH-DPAT (D) 1 103540763 63.64*** .69 
AxD 1 37638245 23.13*** .45 
Error 28 . 1626910 
***n.0001 
**n.001 
*n.o5 
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Table 9 
Summary of Analysis of Variance Performed on Mean 
Number of Rears: Pretreatment Session 7 Blocks 1-6 
Source df MS F Nu 
Between Groups 
Block 1 
Antagonist (A) 1 7969.53 49.42*** .64 
7-OH-DPAT (D) 1 148.78 0.92 
AxD 1 1237.53 7.67* .22 
Error 28 161.27 
Block 2 
Antagonist (A) 1 2812.50 3.07 
7-OH-DPAT (D) 1 10512.50 11.49* .29 
AxD 1 1275.13 1.39 
Error 28 914.92 
Block 3 
Antagonist (A) 1 1458.00 0.68 
7-OH-DPAT (D) 1 20910.13 9.71* .26 
AxD 1 800.00 0.37 
Error 28 2154.53 
Block 4 
Antagonist (A) 1 13736.53 3.70 
7-OH-DPAT (D) 1 39691.53 10.68* .28 
AxD 1 12521.53 3.37 
Error 28 3714.70 
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Table 9 ( continued) 
Source df MS F Nu 
Between Groups 
Block 5 
Antagonist (A) I 57122.00 24.78*** .47 
7-OH-DPAT (D) 1 48984.50 21.25*** .43 
AxD 1 47895.13 20.78*** .43 
Error 28 2304.83 
Block 6 
Antagonist (A) 1 67436.28 20.24*** .42 
7-OH-DPAT (D) 1 168925.78 50.71 *** .64 
AxD 1 61337.53 18.41 ** .40 
Error 28 3331.16 
***u.0001 
**u.001 
*u.05 
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Table 10 
Summary of Analysis of Variance Performed on Mean 
Stereotypic Counts: Pretreatment Session 7 Blocks 1-6 
Source df MS F nu 
Between Groups 
Block 1 
Antagonist (A) 1 55793766 159.11***. .85 
7-OH-DPAT (D) 1 6340361 18.08** .40 
AxD 1 1767200 5.04* .15 
Error 28 350669 
Block 2 
Antagonist (A) 1 16207971 24.66*** .47 
7-OH-DPAT (D) 1 43074121 65.52*** .70 
AxD 1 6741792 10.26* .27 
Error 28 657367 
Block 3 
Antagonist (A) 1 8272278 6.76* .19 
7-OH-DPAT (D) 1 53045000 43.34*** .61 
AxD 1 9658013 7.89* .22 
Error 28 1223826 
Block 4 
Antagonist (A) 1 188225703 16.84** .38 
7-OH-DPAT (D) 1 40338162 37.28*** .57 
AxD 1 12467521 11.52** .29 
Error 28 3714.70 
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Table IO ( continued) 
Source df MS F nu 
Between Groups 
Block 5 
Antagonist (A) 1 30108800 52.86*** .65 
7-OH-DPAT (D) 1 36894050 64.77*** .70 
AxD 1 27840722 48.87*** .64 
Error 28 569644 
Block 6 
Antagonist (A) 1 21516800 15.31 ** .35 
7-OH-DPAT (D) 1 69679013 49.58*** .64 
AxD 1 19546878 13.91 ** .33 
Error 28 19546878 
***Q .0001 
**Q.001 
*Q.05 
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Table 11 
Summary of Analysis of Variance Performed on Mean 
Distance Traveled: 7-OH-DPAT Challenge Session 8 Blocks 1-6 
Source df MS F nu 
Between Groups 
Block 1 
Antagonist (A) 1 3912220 2.84 
7-OH-DPAT (D) 1 20977578 15.21 ** .35 
AxD 1 180399 0.13 
Error 28 1378844 
Block 2 
Antagonist (A) 1 2203137 0.84 
7-OH-DPAT (D) 1 10052960 3.85 
AxD 1 2575639 0.99 
Error 28 2608799 
Block 3 
Antagonist (A) 1 1109409 0.29 
7-OH-DPAT (D) 1 23561778 6.07* .18 
AxD 1 5293916 1.36 
Error 28 3880635 
Block 4 
Antagonist (A) 1 197863 0.05 
7-OH-DPAT (D) 1 25481465 6.87* .20 
AxD 1 2078817 0.56 
Error 28 3707785 
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Table 11 ( continued) 
Source df MS F nu 
Between Groups 
Block 5 
Antagonist (A) 1 6830725 3.00 
7-OH-DPAT (D) 1 44905959 19.73*** .41 
AxD 1 766817 0.34 
Error 28 2276066 
Block 6 
Antagonist (A) 1 22709352 8.37* .23 
7-OH-DPAT (D) 1 36923734 13.62** .33 
AxD 1 9786574 3.61 
Error 28 2711745 
***n .00·01 
**n.001 
*n .o5 
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Table 12 
Summary of Analysis of Variance Performed on Mean 
Number ofRears: 7-OH-DPAT Challenge Session 8 Blocks 1-6 
Source df MS F nu 
Between Groups . 
Block 1 
Antagonist (A) 1 770.28 2.22 
7-OH-DPAT (D) 1 3260.28 9.39* .25 
AxD 1 569.53 1.64 
Error 28 347.10 
Block 2 
Antagonist (A) 1 6188.28 4.06* .13 
7-OH-DPAT (D) 1 2096.28 1.37 
AxD 1 69.03 0.05 
Error 28 1525.64 
Block 3 
Antagonist (A) 1 968.00 0.47 
7-OH-DPAT (D) 1 2701.13 1.30 
AxD 1 1152.00 0.55 
Error 28 2078.53 
Block 4 
Antagonist (A) 1 1313.28 0.40 
7-OH-DPAT (D) 1 13986.28 4.21 * .13 
AxD 1 790.03 0.24 
Error 28 3323.85 
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Table 12 ( continued) 
Source df MS F nu 
Between Groups 
Block 5 
Antagonist (A) 1 10767.78 3.17 
7-OH-DPA-T (D) , 1 67069.53 19.73*** .41 
AxD 1 2502.78 0.74 
Error 28 3399.36 
Block 6 
Antagonist (A) 1 34848.00 8.31 * .23 
7-OH-DPAT (D) 1 69378.13 16.55** .37 
AxD 1 17578.13 4.19* .13 
Error 28 4193.13 
***n.0001 
**n.001 
*n.o5 
I 
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Table 13 
Summary of Analysis of Variance Performed on Mean 
Stereotypic Counts: 7-OH-DPAT Challenge Session 8 Blocks 1-6 
Source df MS F nu 
Between Groups 
Block 1 
Antagonist (A) 1 1681320 2.07 
7-OH-DPAT (D) 1 13149474 16.19** .37 
AxD 1 40257 0.05 
Error 28 812016 
Block 2 
Antagonist (A) 1 57291.10 0.03 
7-OH-DPAT (D) 1 33540.50 0.02 
AxD 1 1356304.50 0.78 
Error 28 1741331.60 
Block 3 
Antagonist (A) 1 4793382 1.83 
7-OH-DPAT (D) 1 2813785 1.08 
AxD 1 3542456.50 1.35 
Error 28 2615037 
Block4 
Antagonist (A) 1 402305 0.24 
7-OH-DPAT (D) 1 4171716 2.52 
AxD 1 11467261 6.94* .20 
Error 28 1652730 
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Table 13 ( continued) 
Source df MS F nu 
Between Groups 
Block 5 
Antagonist (A) 1 28025.30 0.02 
7-OH-DPAT (D) 1 6180249 4.75* .15 
AxD 1 5528643.8 4.25* .13 
Error 28 1301826 
Block 6 
Antagonist (A) 1 2318242.80 1.11 
7-OH-DPAT (D) 1 318202.50 0.15 
AxD 1 29342.50 0.01 
Error 28 2093145.50 
***R.0001 
*R.05 
. ' 
APPENDIXB 
COUNTERBALANCING 
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Sguad # 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
TABLE14 
COUNTERBALANCING 
Subject# Pretreatment Groue 
1 vehicle-vehicle 
2 vehicle-DP AT 
3 SCH-DPAT 
4 SCH -vehicle 
5 SCH - vehicle 
6 SCH-DPAT 
7 vehicle - vehicle 
8 vehicle - DPAT 
9 vehicle - DPAT 
10 vehicle-vehicle 
11 SCH-DPAT 
12 SCH -vehicle 
13 SCH-DPAT 
14 SCH -vehicle 
15 vehicle-DP AT 
16 vehicle-vehicle 
17 vehicle-vehicle 
18 vehicle-DP AT 
19 SCH-DPAT 
20 SCH -vehicle 
21 SCH - vehicle 
22 SCH-DPAT 
23 vehicle - vehicle 
24 vehicle - DP AT 
25 vehicle - DP AT 
26 vehicle-vehicle 
27 SCH-DPAT 
28 SCH -vehicle 
29 SCH-DPAT 
30 SCH -vehicle 
31 vehicle-DP AT 
32 vehicle-vehicle 
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Chamber# 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
I 
2 
3 
4 
I 
2 
3 
4 
